Anticalin developer Pieris and Antibody-drug conjugate specialist Seattle Genetics have agreed to co-develop three bispecific cancer drugs using Seattle Genetic’s cancer targets and Pieris’ co-stimulatory agonist and anticalin platform.
The partnership aims at combining Pieris’ anticalin platform with Seattle Genetics’ monoclonal antibodies portfolio to treat solid tumours and blood cancers. Under the agreement, Seattle Genetics will have the option to bring up to three bispecific candidates into clinical development. Pieris has the option for co-development and co-commercialisation of one programme in the US market sharing development costs and profits 1: 1. Seattle Genetics will fund the other programmes' development.
Read more: http://bit.ly/2EkoxJd